Business Description
Checkpoint Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US1628281073
Description
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | -2.43 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -118.88 | |||||
| WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -70.3 | |||||
| 3-Year EBITDA Growth Rate | 12.5 | |||||
| 3-Year EPS without NRI Growth Rate | 8.1 | |||||
| 3-Year FCF Growth Rate | 5 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 49.05 | |||||
| 9-Day RSI | 47.44 | |||||
| 14-Day RSI | 48.78 | |||||
| 6-1 Month Momentum % | 80.29 | |||||
| 12-1 Month Momentum % | 100.53 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.29 | |||||
| Quick Ratio | 0.29 | |||||
| Cash Ratio | 0.26 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -58.7 | |||||
| Shareholder Yield % | -14.63 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -79817.02 | |||||
| Net Margin % | -98868.09 | |||||
| FCF Margin % | -65440.43 | |||||
| ROA % | -763.77 | |||||
| ROIC % | -2671.94 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 3540 | |||||
| EV-to-EBIT | -4.74 | |||||
| EV-to-Forward-EBIT | -3.17 | |||||
| EV-to-EBITDA | -4.74 | |||||
| EV-to-Forward-EBITDA | -3.17 | |||||
| EV-to-Revenue | 3785.77 | |||||
| EV-to-Forward-Revenue | 543.53 | |||||
| EV-to-FCF | -5.47 | |||||
| Earnings Yield (Greenblatt) % | -21.1 | |||||
| FCF Yield % | -17.79 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CKPT
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Checkpoint Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.047 | ||
| EPS (TTM) ($) | -1.84 | ||
| Beta | 1.72 | ||
| Volatility % | 81.81 | ||
| 14-Day RSI | 48.78 | ||
| 14-Day ATR ($) | 0.400631 | ||
| 20-Day SMA ($) | 3.89525 | ||
| 12-1 Month Momentum % | 100.53 | ||
| 52-Week Range ($) | 1.38 - 4.5 | ||
| Shares Outstanding (Mil) | 48.83 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Checkpoint Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Checkpoint Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Checkpoint Therapeutics Inc Frequently Asked Questions
What is Checkpoint Therapeutics Inc(CKPT)'s stock price today?
The current price of CKPT is $3.64. The 52 week high of CKPT is $4.50 and 52 week low is $1.38.
When is next earnings date of Checkpoint Therapeutics Inc(CKPT)?
The next earnings date of Checkpoint Therapeutics Inc(CKPT) is 2025-03-21 Est..
Does Checkpoint Therapeutics Inc(CKPT) pay dividends? If so, how much?
Checkpoint Therapeutics Inc(CKPT) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers